JBS N.V. announced on November 9, 2026, that its Brazilian subsidiary, JBS S.A., has entered into a share purchase agreement to acquire 100% of the outstanding shares of Flora Produtos de Higiene e Limpeza S.A. The transaction, valued at approximately US$542 million, is intended to expand JBS's consumer products platform and marks the company's entry into the beauty and personal care market.
According to the filing, Flora is a Brazilian company with more than 45 years of history, ranking among the country's five largest companies in bath products and laundry care. For the twelve months ended September 2026, Flora reported annual net revenue of R$2.9 billion (US$531 million). The company operates five manufacturing facilities, seven distribution centers, and a research and development center, and employs over 4,200 people. Its portfolio includes leading Brazilian brands such as Minuano, Francis, Neutrox, and OX.
The acquisition is structured as a related-party transaction with J&F S.A. and Colorado Fundo de Investimento em Participações em Cadeias Produtivas Agroindustriais – FIP FIAGRO. JBS S.A. has agreed to pay a purchase price of R$2.968 billion (US$367 million) in equity consideration, which will be paid entirely in Class A common shares of JBS or Brazilian depositary receipts (BDRs). The number of shares to be issued will be determined based on a reference price of R$66.82916 per share, calculated using the volume-weighted average closing price of JBS shares on the New York Stock Exchange for the 30 trading sessions ending November 5, 2026.
In addition to Flora, JBS announced the acquisition of Canal Rural Produções Ltda., a Brazilian media company focused on agribusiness. That transaction is valued at US$11 million (R$61 million) on a cash-free, debt-free basis, with the final price subject to adjustments for net debt at closing. Both acquisitions are expected to close in December 2026, subject to customary closing conditions.
JBS stated that the transaction includes the assumption of Flora's debt. Based on Flora's EBITDA contribution and the transaction structure, the company expects the acquisition to have no impact on its net leverage ratio. The deal is supported by studies prepared by specialized independent institutions and has been approved by JBS's audit committee and board of directors.
